Death Spiral Financing: How to Spot It, Avoid It, and Survive It

Death spiral financing — toxic convertible note structures — has ended more micro-cap public companies than bad products, weak management, or market downturns combined. The mechanism is elegant in its destruction: a company in need of capital takes a convertible note with variable conversion terms, and the note holder profits by converting and selling until the share price reaches zero.

Most CEOs sign these term sheets believing they have no other options. Often, better options exist.

The Classic Structure

• •The company receives $1M–$5M in exchange for a convertible note
• •Conversion price is set at a discount to market — typically 20–40% below the lowest closing price in the prior 10–30 trading days
• •The conversion price resets as the stock price falls
• •There is no floor

The holder converts, immediately sells, depresses the price, resets the conversion lower, converts again. This is not an accident. It is the business model.

Warning Signs in a Term Sheet

If you see any of these terms, stop and get independent counsel:

• •Conversion price tied to a trailing VWAP or lowest closing price
• •"Most Favored Nation" clauses that match any future financing terms
• •Anti-dilution provisions that reset downward without a floor
• •Registration rights requiring share registration within 30–60 days
• •Default provisions triggered by stock price thresholds
• •Investors who approached you, rather than the reverse
• •Term sheets delivered with 48–72 hour deadlines

Who Offers This Capital

They target companies with share prices under $5, market caps under $100M, recent failed registered offerings, and visible near-term cash runway problems. They find you. That is a data point in itself.

Alternatives That Actually Exist

• •ATM offerings through a registered broker-dealer — slower but non-toxic
• •PIPE with institutional investors — requires stronger equity story but carries fixed terms
• •Shelf registration if you have an effective S-3
• •Strategic partnerships with capital components — JVs where the partner brings capital
• •Venture debt from specialty lenders familiar with small-cap public companies

None are as fast as a toxic note. That speed premium is the product you are buying — and it is enormously expensive.

If You Have Already Signed

The situation is recoverable in some cases. Restructuring or refinancing the toxic note is possible depending on outstanding balance, conversion pace, and remaining cash position.

If you are evaluating a convertible financing, get your free algo score — it will show how the structure is likely to affect your institutional perception before you make a decision.